PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant challenge with...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Marayati, Raoud, Stafman, Laura L., Williams, Adele P., Bownes, Laura V., Quinn, Colin H., Aye, Jamie M., Stewart, Jerry E., Yoon, Karina J., Anderson, Joshua C., Willey, Christopher D., Beierle, Elizabeth A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7966748/
https://ncbi.nlm.nih.gov/pubmed/33727604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85289-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi